Aurobindo Pharma Limited — Q3 FY25
Aurobindo Pharma delivered its highest-ever quarterly revenue of INR 7,979 crore in Q3 FY25, driven by robust US base product sales, strong European growth (+23% YoY), and expan...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY25
Penicillin G breakeven by Q4 FY25
Expect to achieve breakeven at the penicillin G facility by Q4 FY25, with positive contribution from FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1